Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...
On December 15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting ...
For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...
While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...
The best weight loss medication for men includes semaglutide (Ozempic , Wegovy ), tirzepatide (Mounjaro , Zepbound ), and ...
Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...
How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...
9h
Federal judges consolidate GLP-1 vision loss lawsuits, sends cases to federal judge in Pennsylvania
Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...
We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback